Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$4.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue growth is crucial for assessing the company's market demand and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with serious diseases. Operating in the health care sector, Dianthus aims to address unmet medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of -$0.85, which was better than the expected -$1.17, resulting in a positive surprise of 27.04%. The stock reacted positively with a 1.01% increase the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Dianthus's upcoming earnings report, especially after the recent positive surprise in Q1-2026. However, the lack of analyst estimates and management guidance creates uncertainty.

Bull Case

If Dianthus can continue to outperform expectations on EPS and show signs of revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet even the lower expectations or shows no improvement in its financial metrics, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

This will give investors insight into the company's profitability and whether it can maintain or improve its performance from the previous quarter.

What are the revenue projections for the upcoming quarter?

Understanding revenue growth is critical for assessing the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dianthus's ability to improve its EPS and revenue metrics based on recent trends in the biotech sector.

Supporting Evidence

The company's recent EPS surprise indicates potential for continued improvement.

Options pricing suggests a significant expected move, which may reflect investor confidence in a positive outcome.

Key Risk

If the EPS comes in significantly better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can sustain its recent positive momentum or if it will revert to its previous performance levels.

Bull Confirmed If

A reported EPS of -$0.70 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests the stock could rise by around 4.47%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss expectations, history suggests a potential drop of around 4.47%, leading to increased skepticism about its growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies to improve EPS.
4Insights into market demand for their products.
5Any changes in regulatory environment affecting their operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.

N/A

Revenue

Revenue growth is crucial for assessing the company's market demand and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Dianthus can continue to outperform expectations on EPS and show signs of revenue growth, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet even the lower expectations or shows no improvement in its financial metrics, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

This will give investors insight into the company's profitability and whether it can maintain or improve its performance from the previous quarter.

What are the revenue projections for the upcoming quarter?

Understanding revenue growth is critical for assessing the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dianthus's ability to improve its EPS and revenue metrics based on recent trends in the biotech sector.

Supporting Evidence

The company's recent EPS surprise indicates potential for continued improvement.

Options pricing suggests a significant expected move, which may reflect investor confidence in a positive outcome.

Key Risk

If the EPS comes in significantly better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can sustain its recent positive momentum or if it will revert to its previous performance levels.

Bull Confirmed If

A reported EPS of -$0.70 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests the stock could rise by around 4.47%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.

Miss

Should the company miss expectations, history suggests a potential drop of around 4.47%, leading to increased skepticism about its growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies to improve EPS.
4Insights into market demand for their products.
5Any changes in regulatory environment affecting their operations.